1,171 件 ・ 関連度順
概要と使いどころ
Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Performs time-to-event analysis for clinical trials including Cox proportional hazards regression with PH diagnostics, restricted mean survival time (RMST) under non-PH, competing risks via Fine-Gray vs cause-specific Cox, weighted log-rank and MaxCombo for non-proportional hazards, recurrent events (Andersen-Gill, PWP, WLW), and interval-censored data. Use when analyzing time-to-event endpoints (OS, PFS, DOR, TTR, TTNT) in oncology or other clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.
日本語の概要は準備中です。原文の説明を表示しています。
Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.
日本語の概要は準備中です。原文の説明を表示しています。
Serves LLMs with high throughput using vLLM's PagedAttention and continuous batching. Use when deploying production LLM APIs, optimizing inference latency/throughput, or serving models with limited GPU memory. Supports OpenAI-compatible endpoints, quantization (GPTQ/AWQ/FP8), and tensor parallelism.
日本語の概要は準備中です。原文の説明を表示しています。
Builds QSAR / QSPR models using chemprop D-MPNN, MolFormer, Uni-Mol, ChemBERTa, random forest baselines, and Gaussian processes with explicit handling of OECD 5 principles, applicability domain (kNN, leverage, conformal prediction, Mahalanobis), scaffold-balanced splits, ensemble uncertainty, calibration (Platt, isotonic), feature importance (SHAP, atomic attribution), and prospective validation. Use when building target-specific predictive models from in-house bioassay data, ADMET endpoints, or selectivity profiles.
日本語の概要は準備中です。原文の説明を表示しています。
Querying Stellar chain data via Stellar RPC (preferred) and Horizon (legacy). Covers RPC JSON-RPC methods, Horizon REST endpoints, streaming, pagination, historical queries, Hubble/Galexie for deep history, and the RPC/Horizon migration story. Use when reading balances, transactions, operations, ledgers, contract events, or building any indexer/analytics workflow.
日本語の概要は準備中です。原文の説明を表示しています。
VenTu is a static export on GitHub Pages — no Node runtime at request time. Use when adding routes, auth, alerts, forms, API endpoints, or anything that could depend on a server.
日本語の概要は準備中です。原文の説明を表示しています。
Runs the CARLA Leaderboard evaluator over a set of routes with your agent — routes/routes-subset/repetitions/track selection, checkpoint and live-results endpoints, resume after a crash, recording, and the debug levels — for leaderboard 1.0, 2.0 or 2.1. Preflights the whole stack (version pairing, maps, ports, agent class, sensor budget) before spending hours, and hands the world back in async mode. Use when the user asks to "run the leaderboard", "evaluate my agent", "run routes_training", "resume an evaluation", or "reproduce my submission locally".
日本語の概要は準備中です。原文の説明を表示しています。
A2A agent card JSON templates with schema validation and examples for different agent types. Use when creating agent cards, implementing A2A protocol discovery, setting up agent metadata, configuring authentication schemes, defining agent capabilities, or when user mentions agent card, agent discovery, A2A metadata, service endpoint configuration, or agent authentication setup.
日本語の概要は準備中です。原文の説明を表示しています。
MUST USE for building FastAPI/REST API applications with Aerospike database (aerospike-py Rust/PyO3 async client). Covers AsyncClient lifespan management, FastAPI Depends injection, aerospike_py exception-to-HTTP-status mapping (RecordNotFound→404, RecordExistsError→409, BackpressureError→503, AerospikeTimeoutError→504), POLICY_EXISTS_CREATE_ONLY/UPDATE_ONLY for CRUD semantics, NamedTuple attribute access (record.bins not tuple unpacking), client.ping() readiness probe, batch_read returning dict, batch_write with in_doubt retry signal, and global AerospikeError handler. Triggers on: FastAPI + Aerospike, REST API + aerospike-py, CRUD API with Aerospike, client.ping() health probe, batch_read/batch_write endpoint, web server/HTTP service backed by Aerospike NoSQL, uvicorn + Aerospike.
日本語の概要は準備中です。原文の説明を表示しています。
Web API development conventions for Adynato projects. Covers API routes, middleware, authentication, error handling, validation, and response formats for Next.js and Node.js backends. Use when building or modifying API endpoints, server actions, or backend logic.
日本語の概要は準備中です。原文の説明を表示しています。
Creates TanStack Query hooks for API features with authentication. Use when connecting frontend to backend endpoints, creating data fetching hooks.
日本語の概要は準備中です。原文の説明を表示しています。
Analyze, plan, and execute Adobe SDK upgrades — including the critical JWT-to-OAuth migration, PDF Services SDK v3-to-v4, and Photoshop API endpoint changes (cutout v1 to remove-background v2). Trigger with phrases like "upgrade adobe", "adobe migration", "adobe breaking changes", "update adobe SDK", "jwt to oauth".
日本語の概要は準備中です。原文の説明を表示しています。
Implement REST APIs in ABP Framework with AppServices, DTOs, pagination, filtering, and authorization. Use when building API endpoints for ABP applications.
日本語の概要は準備中です。原文の説明を表示しています。
Configures integration tests with WebApplicationFactory and Testcontainers. Provides test database setup, authentication helpers, and utilities for testing API endpoints with real dependencies.
日本語の概要は準備中です。原文の説明を表示しています。
Maps between gene identifier systems (Ensembl, Entrez, HGNC symbol, UniProt, RefSeq, MANE) using AnnotationDbi, biomaRt, mygene, pyensembl, and Ensembl REST. Encodes Ensembl version stripping with GENCODE _PAR_Y preservation, the Ziemann 2016 Excel autocorrect debacle and Bruford 2020 HGNC renames (SEPT*->SEPTIN*, MARCH*->MARCHF*, MARC*->MTARC*, DEC1->DELEC1), OCT4/POU5F1 alias resolution, biomaRt archive endpoints for release pinning, the `filters` (plural) gotcha, MANE Select for clinical reporting, cross-species orthology via Ensembl Compara / OMA / OrthoDB, and tx2gene construction for tximport. Use when converting gene IDs across systems, handling renamed symbols, building tx2gene, pinning to a specific Ensembl release for reproducibility, or mapping cross-species orthologs.
日本語の概要は準備中です。原文の説明を表示しています。
Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.
日本語の概要は準備中です。原文の説明を表示しています。
Query the Ensembl REST API for gene/transcript/protein lookup, sequence retrieval, comparative genomics (Compara), variant effect prediction (VEP), regulatory features, and cross-species ortholog/paralog calls. Use when pulling Ensembl-native data (Ensembl Gene IDs, version-pinned releases, archive endpoints for reproducibility), gene/transcript/exon structure with stable IDs, or VEP for variant annotation. Encodes the 15 req/sec rate limit, archive (e110.rest.ensembl.org) for reproducibility, Ensembl divisions (vertebrates / plants / fungi / metazoa / bacteria), and the symbol-vs-ID stability problem.
日本語の概要は準備中です。原文の説明を表示しています。
Quality control for pooled CRISPR screens covering library representation, Gini index, log-skew, replicate Pearson and Spearman concordance, essentialome precision-recall AUC against CEGv2 (Hart 2017), Cas9 cut-toxicity diagnostics, copy-number amplicon detection (Aguirre 2016 / Munoz 2016), bottleneck propagation through plasmid pool, infection, selection, and endpoint stages, MOI verification, and DepMap-style screen-quality scoring. Use when assessing screen quality before hit calling, deciding whether to repeat or rescue a screen, diagnosing low-confidence hits, choosing between MAGeCK / BAGEL2 / Chronos based on quality grade, picking a normalization strategy from QC signatures, or evaluating whether an in-vivo screen retained adequate library complexity.
日本語の概要は準備中です。原文の説明を表示しています。
Bulk-query Ensembl BioMart (and other BioMart instances) for cross-database ID mapping, gene/transcript/exon coordinates, and ortholog tables. Use when batch-converting Ensembl IDs to other namespaces (HGNC, RefSeq, UniProt, Entrez), pulling gene coordinate tables for thousands of genes, building ortholog wide-tables across species, or replacing slow Ensembl REST loops with one-shot bulk export. Encodes BioMart's XML query format, R biomaRt vs Python pybiomart trade-off, mart-vs-dataset hierarchy, and the URL endpoint that's BioMart-specific (separate from rest.ensembl.org).
日本語の概要は準備中です。原文の説明を表示しています。
Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.
日本語の概要は準備中です。原文の説明を表示しています。
Performs time-to-event analysis for clinical trials including Cox proportional hazards regression with PH diagnostics, restricted mean survival time (RMST) under non-PH, competing risks via Fine-Gray vs cause-specific Cox, weighted log-rank and MaxCombo for non-proportional hazards, recurrent events (Andersen-Gill, PWP, WLW), and interval-censored data. Use when analyzing time-to-event endpoints (OS, PFS, DOR, TTR, TTNT) in oncology or other clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Implements missing-data sensitivity analyses for confirmatory clinical trials including MMRM under MAR (with Kenward-Roger correction), reference-based multiple imputation (J2R, CR, CIR, LMCF per Carpenter-Roger 2013), Permutt delta-adjustment / tipping-point analysis, pattern-mixture identifying restrictions (CCMV, NCMV, ACMV), and the Cro vs Bartlett variance debate. Use when handling missing primary or secondary endpoint data in regulatory submissions following NRC 2010 and ICH E9(R1).
日本語の概要は準備中です。原文の説明を表示しています。